ASP Isotopes (NASDAQ:ASPI) Stock Price Down 3.2% - Should You Sell?

ASP Isotopes Inc. (NASDAQ:ASPI - Get Free Report) traded down 3.2% on Tuesday . The stock traded as low as $8.35 and last traded at $8.31. 2,878,708 shares were traded during mid-day trading, an increase of 12% from the average session volume of 2,562,950 shares. The stock had previously closed at $8.59.

Analysts Set New Price Targets

Separately, Canaccord Genuity Group raised their price target on shares of ASP Isotopes from $8.50 to $11.00 and gave the company a "buy" rating in a research report on Wednesday, May 21st.

ASP Isotopes Stock Performance

The firm has a market cap of $568.97 million, a P/E ratio of -12.43 and a beta of 3.40. The company has a current ratio of 7.55, a quick ratio of 7.54 and a debt-to-equity ratio of 0.80. The company's 50-day moving average is $5.92 and its two-hundred day moving average is $5.45.

Insiders Place Their Bets

In other ASP Isotopes news, COO Robert Ainscow sold 66,666 shares of ASP Isotopes stock in a transaction that occurred on Tuesday, April 15th. The shares were sold at an average price of $5.75, for a total transaction of $383,329.50. Following the transaction, the chief operating officer now owns 1,553,326 shares of the company's stock, valued at $8,931,624.50. This trade represents a 4.12% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Paul Elliot Mann sold 316,667 shares of ASP Isotopes stock in a transaction that occurred on Tuesday, April 15th. The stock was sold at an average price of $5.75, for a total transaction of $1,820,835.25. Following the transaction, the chief executive officer now directly owns 7,948,787 shares in the company, valued at approximately $45,705,525.25. This represents a 3.83% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 766,667 shares of company stock valued at $4,358,502 in the last 90 days. 21.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ASP Isotopes

Large investors have recently modified their holdings of the stock. JPMorgan Chase & Co. increased its stake in shares of ASP Isotopes by 854.6% during the 4th quarter. JPMorgan Chase & Co. now owns 211,893 shares of the company's stock worth $960,000 after purchasing an additional 189,697 shares during the last quarter. Price T Rowe Associates Inc. MD increased its stake in shares of ASP Isotopes by 14.6% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 21,646 shares of the company's stock worth $99,000 after purchasing an additional 2,757 shares during the last quarter. Avantax Advisory Services Inc. purchased a new stake in shares of ASP Isotopes during the 4th quarter worth approximately $45,000. Northern Trust Corp increased its stake in shares of ASP Isotopes by 15.5% during the 4th quarter. Northern Trust Corp now owns 435,688 shares of the company's stock worth $1,974,000 after purchasing an additional 58,525 shares during the last quarter. Finally, Wells Fargo & Company MN increased its stake in shares of ASP Isotopes by 57.4% during the 4th quarter. Wells Fargo & Company MN now owns 24,472 shares of the company's stock worth $111,000 after purchasing an additional 8,925 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company's stock.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235.